Endo International plc
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Endo International plc Endo International plc is a specialty pharmaceutical company that develops, manufactures, markets and distributes branded pharmaceuticals, generic drugs and sterile injectables; its portfolios encompass products for urology, orthopedics, immunology, ophthalmology, pain management, oncology, women's health, endocrinology and central nervous system disorders, including key brands such as XIAFLOX, SUPPRELIN LA, TESTOPEL, NASCOBAL Nasal Spray, AVEED, PERCOCET and VOLTAREN Gel, alongside differentiated generics in solid oral extended-release and immediate-release formulations, liquids, semi-solids, patches, powders, ophthalmics and sprays. Founded in 1920 and headquartered in Dublin, Ireland, with primary U.S. operations in Malvern, Pennsylvania, the company maintains global manufacturing, R&D and laboratory facilities in the U.S., Ireland, Canada and India, serving healthcare providers, patients and customers primarily in North America through a portfolio exceeding 3.6 million monthly prescriptions and supported by ongoing sterile injectables R&D projects. In recent developments, Endo emerged from Chapter 11 bankruptcy proceedings in April 2024 as Endo, Inc. following court confirmation of its reorganization plan that sold substantially all assets to a new entity backed by first-lien debt holders, significantly reducing indebtedness and resolving litigation overhang; it completed a merger with Mallinckrodt plc in August 2025 to form a diversified therapeutics leader valued at approximately $6.7 billion, after which the combined entity's generics and sterile injectables businesses spun off as independent Par Health while the specialty therapeutics operations rebranded as Keenova Therapeutics in November 2025, enhancing scale in branded products for rare and stigmatized conditions alongside robust generic manufacturing.
Endo International plc (ENDPQ) Q2 2025 Earnings Call Transcript
Endo International plc (ENDPQ) Q1 2025 Earnings Call Transcript
Endo International plc (ENDPQ) Q4 2024 Earnings Call Transcript
Endo International plc (ENDPQ) Q3 2024 Earnings Call Transcript
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
Drugmaker Endo receives US court approval for bankruptcy restructuring
Endo Announces Confirmation of Plan of Reorganization
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS
Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER
Drugmaker Endo reaches $465 mln bankruptcy settlement with US government
Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open
Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada
Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting
ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE TRANSACTION
Endo Launches Unscripted Video Series With Real Peyronie's Disease Patients
ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS
Endo Launches Colchicine Capsules, Generic Version of MITIGARE®
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting